Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EARLY: Alirocumab in Myocardial Infarction
NCT03750760Phase 4Withdrawn
- Sponsor
- Imperial College London
- Start
- Jan 2020
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of alirocumab in myocardial infarction (MI) and dyslipidemia (2 arms), sponsored by Imperial College London. Primary endpoint: Percentage change in LDL-C at 2 weeks. Planned start Jan 2020; status: withdrawn.
02
Drugs
alirocumab
03
Conditions
myocardial infarction (MI)dyslipidemia
Beyond the preview
Go deeper on NCT03750760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03750760.